Investor Presentaiton

Thermostability Significant progress toward improved thermostability шипишит шиппишит шитиши ушитиши шипишит Monovalent LNP Multivalent LNP Prototype LNP demonstrating 12-months+ stability as 2-8°C liquid Change in % mRNA Integrity 100- 75- 50- 25- Prototype LNP 0 0 3 6 9 12 Months 88 Vaccines Investor Event sanofi Scale-up Industrial environment Increasing complexity QIV LNP demonstrating ~9 months stability as 2-8°C liquid 100 75- 50- Liquid LNP (Control) QIV LNP candidate + Excipient Next step: Achieve large scale batches Change in % mRNA Integrity 25 0 6 9 Months

View entire presentation